Free Trial
OTCMKTS:BIOVF

Swedish Orphan Biovitrum 10/30/2023 Earnings Report

Swedish Orphan Biovitrum logo
$29.25 0.00 (0.00%)
As of 07/1/2025

Swedish Orphan Biovitrum EPS Results

Actual EPS
$0.05
Consensus EPS
$0.09
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Swedish Orphan Biovitrum Revenue Results

Actual Revenue
$478.11 million
Expected Revenue
$443.96 million
Beat/Miss
Beat by +$34.15 million
YoY Revenue Growth
N/A

Swedish Orphan Biovitrum Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Swedish Orphan Biovitrum's next earnings date is estimated for Wednesday, July 16, 2025, based on past reporting schedules.

Conference Call Resources

Swedish Orphan Biovitrum Earnings Headlines

Sobi and Apellis Amend Royalty Agreement for Aspaveli
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
See More Swedish Orphan Biovitrum Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Swedish Orphan Biovitrum? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Swedish Orphan Biovitrum and other key companies, straight to your email.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) (OTCMKTS:BIOVF), commonly known as Sobi, is a Stockholm-based biopharmaceutical company dedicated to the development and delivery of therapies for rare diseases and specialty conditions. Established in 2007 through the merger of Swedish Orphan International and Biovitrum, Sobi has built a global footprint with commercial operations across Europe, North America, Asia Pacific and select markets in Latin America and the Middle East. The company’s strategic focus on orphan drugs reflects a commitment to addressing unmet medical needs in patient populations that are often underserved by larger pharmaceutical players.

Sobi’s core business activities encompass research and development, manufacturing and commercialization of innovative treatments in hematology, immunology, rheumatology and metabolic disorders. Its current product portfolio includes extended half-life therapies for hemophilia, targeted immunomodulators for rare inflammatory conditions and enzyme replacement products for inherited metabolic diseases. In addition to internally developed assets, Sobi collaborates with global partners through licensing agreements, co-development arrangements and distribution partnerships to broaden access to its specialized medicines.

Over the past decade, Sobi has expanded its R&D capabilities through strategic acquisitions and alliances, while strengthening its commercial presence via regional subsidiaries such as Sobi Inc. in the United States and affiliates in Japan and Canada. Its pipeline features next-generation biologics and gene therapy candidates aimed at advancing care for patients with life-threatening genetic disorders. The company places particular emphasis on patient access programs and health economics to support reimbursement and market uptake in diverse healthcare systems.

Under the leadership of Chief Executive Officer Guido Oelkers and a management team with extensive experience in specialty pharmaceuticals, Sobi operates with a patient-centric ethos and a robust governance framework. The company’s board of directors comprises industry veterans and medical experts who oversee corporate strategy and ensure adherence to ethical, regulatory and quality standards. With a mission to make a difference for people affected by rare diseases, Sobi continues to invest in innovation, sustainability and partnerships that further its vision of transforming rare disease care worldwide.

View Swedish Orphan Biovitrum Profile

More Earnings Resources from MarketBeat